64 134

Cited 18 times in

Serum growth arrest-specific protein 6 levels are a reliable biomarker of disease activity in systemic lupus erythematosus.

Authors
Kim, HA; Nam, JY; Jeon, JY; An, JM; Jung, JY; Bae, CB; Suh, CH
Citation
Journal of clinical immunology, 33(1):143-150, 2013
Journal Title
Journal of clinical immunology
ISSN
0271-91421573-2592
Abstract
PURPOSE: Growth arrest-specific protein 6 (Gas6) has been suggested to be a biomarker of disease activity in patients with systemic lupus erthematosus (SLE). We investigated the clinical significance of this protein in Korean SLE.



METHODS: Blood samples were collected from 150 SLE patients and 50 normal controls (NC). In addition, follow-up samples were collected from 50 SLE patients.



RESULTS: Serum Gas6 levels of SLE patients (43.01 ± 28.02 ng/mL) were higher than those of NC (20.15 ± 9.23 ng/mL, p<0.001). When evaluated sensitivity and specificity of the Gas6 for diagnosing SLE using ROC curves, the sensitivity and specificity were 72.7 % and 84 % with a cut-off value of 25.3 ng/mL. In the ROC analysis of Gas6, anti-dsDNA antibody, ESR, complement 3 and complement 4 to identify patients with active lupus, area under the curve (AUC) of Gas6 was highest with 0.763. Serum Gas6 levels were significantly higher in the patients with serositis (70.04 ± 30.85 ng/mL) and renal disorder (65.66 ± 32.28 ng/mL) compared to those without (41.88 ± 27.44 ng/mL, p=0.033, 40.3 ± 26.33 ng/mL, p=0.001, respectively). Gas6 levels were correlated positively with anti-dsDNA antibody (r=0.199, p=0.015), ESR (r=0.204, p=0.013) and SLEDAI (r=0.512, p<0.001). In addition, serum Gas6 levels were correlated negatively with hemoglobin (r= -0.165, p=0.043), lymphocyte count (r= -0.165, p=0.043), complement 3 (r= -0.343, p<0.001) and complement 4 (r= -0.316, p<0.001). Furthermore, change in serum Gas6 levels was correlated with change in SLEDAI levels in the SLE patients that were followed up (r=0.524, p<0.001).



CONCLUSION: These results suggest that serum Gas6 can be a reliable clinical marker for monitoring disease activity and treatment response in SLE.
MeSH terms
AdultBiological Markers/bloodFemaleFollow-Up StudiesHumansInflammation Mediators/blood/physiologyIntercellular Signaling Peptides and Proteins/biosynthesis/*bloodLupus Erythematosus, Systemic/*blood/diagnosis/*immunologyMiddle AgedReproducibility of ResultsRepublic of KoreaTreatment Outcome
DOI
10.1007/s10875-012-9765-1
PMID
22914895
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Rheumatology
AJOU Authors
김, 현아전, 자영정, 주양서, 창희
Files in This Item:
fulltext not available.txtDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse